uniQure NV (QURE)

43.64
0.22 0.51
NASDAQ : Health Technology
Prev Close 43.42
Open 43.67
Day Low/High 43.29 / 44.77
52 Wk Low/High 21.98 / 82.49
Volume 350.29K
Avg Volume 580.40K
Exchange NASDAQ
Shares Outstanding 42.74M
Market Cap 1.84B
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

UniQure To Participate In Multiple Upcoming Industry Conferences In October

UniQure To Participate In Multiple Upcoming Industry Conferences In October

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept.

UniQure Announces Pricing Of Its Public Offering

UniQure Announces Pricing Of Its Public Offering

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept.

UniQure Announces Proposed Public Offering

UniQure Announces Proposed Public Offering

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept.

UniQure To Participate In Multiple Upcoming Industry Conferences In September

UniQure To Participate In Multiple Upcoming Industry Conferences In September

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug.

UniQure Announces Leadership Promotions And Executive Transition

UniQure Announces Leadership Promotions And Executive Transition

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug.

UniQure Announces Second Quarter 2019 Results And Highlights Recent Company Progress

UniQure Announces Second Quarter 2019 Results And Highlights Recent Company Progress

~ Presented 36 Weeks of Follow-up Data from Phase IIb Study of AMT-061 Demonstrating Sustained Increases in FIX Activity at up to 54% of Normal ~ ~ Continuing Patient Recruitment in HOPE-B Pivotal Study of AMT-061, With Completion of Enrollment Expected...

UniQure To Participate In Multiple Upcoming Industry Conferences

UniQure To Participate In Multiple Upcoming Industry Conferences

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 26, 2019 (GLOBE NEWSWIRE) -- uniQure N.

UniQure Announces 36 Weeks Of Follow-Up Data From Phase IIb Study Of AMT-061 And Long-Term Follow-Up Data For AMT-060 In Patients With Hemophilia B

UniQure Announces 36 Weeks Of Follow-Up Data From Phase IIb Study Of AMT-061 And Long-Term Follow-Up Data For AMT-060 In Patients With Hemophilia B

~ FIX Activity Up to 54% of Normal, with Mean of 45% of Normal, at 36 WeeksAfter Administration of AMT-061 in Phase IIb Study ~ ~ Clinical Benefit and Tolerability of AMT-060 Maintained in All Patients Through up to 3.

UniQure Jumps on Report It's Exploring a Possible Sale

UniQure Jumps on Report It's Exploring a Possible Sale

A report says the biotechnology company is exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy.

UniQure Reaches Analyst Target Price

UniQure Reaches Analyst Target Price

In recent trading, shares of uniQure N. .

First Week Of QURE July 2019 Options Trading

First Week Of QURE July 2019 Options Trading

Investors in uniQure N. .

UniQure Becomes Oversold (QURE)

UniQure Becomes Oversold (QURE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

3 Cutting-Edge Biotech Stocks That Can Double in Value

3 Cutting-Edge Biotech Stocks That Can Double in Value

These three "strong buy" biotech stocks are primed for outsized growth in the next 12 months. Here's why.

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Here's what you need to know for Monday, April 9.

QURE Crosses Above Average Analyst Target

QURE Crosses Above Average Analyst Target

In recent trading, shares of uniQure N. .

UniQure Announces Publication In The Journal Blood Of Clinical Data From Phase I/II Trial Of AMT-060 In Patients With Severe Hemophilia B

UniQure Announces Publication In The Journal Blood Of Clinical Data From Phase I/II Trial Of AMT-060 In Patients With Severe Hemophilia B

Data Demonstrate Clinical Effectiveness and Superior Immunogenicity Profile of AAV5 Gene Therapy in Severe and Moderate-Severe Hemophilia B Patients

7 Winners and Losers From Biggest Biotech Conference of 2017

7 Winners and Losers From Biggest Biotech Conference of 2017

Here are how some of the conference presenters are performing on the market Wednesday

UniQure Announces Presentations At The 59th American Society Of Hematology (ASH) Annual Meeting

UniQure Announces Presentations At The 59th American Society Of Hematology (ASH) Annual Meeting

~ New Nonclinical Data on AMT-061 to be Presented Saturday, December 9, 2017 ~

TheStreet Quant Rating: D- (Sell)